Virpax reports on progress of Envelta

Envelta is the company’s non-opioid pain product candidate for acute and chronic pain

LogiPharma launches Asian focused summit, coming to Singapore in June 2023

The summit encompasses multiple verticals, spanning from pharmaceuticals, biotech, life sciences, and the Healthcare sector to ensure an unbiased and comprehensive view on the future of the function.

SK Capital completes acquisition of Apotex

Dozee Raises $6 million to bolster its ambition of ‘HarBedDozeeBed’

Dozee plans to further tap over 2,000 hospitals in more than 100 districts

Biocon awarded Silver Medal by EcoVadis for sustainability accomplishments

For the year 2022, Biocon bettered its score in all the four EcoVadis themes – Environment (70), Labor & Human Rights (70), Ethics (60), and Sustainable Procurement (60)

CBC Group appoints Abbas Hussain as Operating Partner

Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions

Hutchmed completes rolling submission of NDA to USFDA for fruquintinib

NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China

Alembic receives USFDA final approval for Brimonidine Tartrate Ophthalmic Solution

Brimonidine Tartrate Ophthalmic Solution is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure

Lupin receives tentative approval from USFDA for Valbenazine capsules

Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).

Lupin announces completion of pharmacovigilance inspection by USFDA

The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide